Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Dezember 2021 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma’s Vitreous Substitute Vitargus Presented at 14th APVRS Congress

Fremont, CA, Dec. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
15. Dezember 2021 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award

Fremont, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
09. Dezember 2021 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement

Fremont, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
15. November 2021 16:33 ET | Quelle: ABVC BioPharma, Inc.

ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results

FREMONT, CA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy...
11. November 2021 09:00 ET | Quelle: ABVC BioPharma, Inc.

ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M

FREMONT, CA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc.(Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy...
27. Oktober 2021 08:30 ET | Quelle: ABVC BioPharma, Inc.

Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites

ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study Completion of the Study Expected by the End of 2022 FREMONT, CA, Oct. 27, 2021 (GLOBE...
12. Oktober 2021 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research

Restructured Venture Also Seeks Licensing Partners for ABVC FREMONT, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical...
13. September 2021 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

Completion of the Study Expected by the End of 2022 FREMONT, CA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
01. September 2021 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments

FREMONT, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
30. August 2021 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma Report Updated by Zacks/SCR

FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...

Vorherige Seite